Research Guide
Tesamorelin
Also known as: Egrifta, TH9507
FDA-approved GHRH analogue for visceral fat reduction and IGF-1 elevation.
Overview
Tesamorelin is a stabilised analogue of human GHRH (growth-hormone-releasing hormone), FDA-approved as Egrifta for HIV-associated lipodystrophy. It is the only growth-hormone-releasing research compound with full clinical approval and is widely studied for visceral fat reduction.
Mechanism of action
Tesamorelin binds the GHRH receptor on the anterior pituitary, triggering pulsatile endogenous GH release. Because it works upstream of the pituitary, it preserves the natural negative feedback loop, unlike exogenous HGH.
Reference range (research literature)
Clinical protocols use 2mg subcutaneously daily, typically administered before sleep to align with natural GH pulses.
Half-life
Roughly 26 minutes systemically, but downstream GH and IGF-1 effects persist for hours.
Reconstitution
Reconstitute the 10mg vial with 2ml bacteriostatic water. Each 0.4ml = 2mg. Refrigerate; use within 14 days for peak potency.
Comparisons
vs CJC-1295
Both stimulate GH release; Tesamorelin is clinically validated and more potent per dose.
vs HGH
Tesamorelin preserves natural pulsatility; exogenous HGH overrides it.
Commonly researched stacks
- MOTS-C (metabolic recovery)
- Retatrutide (fat loss research)
Frequently asked
Does it affect cortisol or prolactin?
Clinical data shows minimal effect on either.
Morning or evening dosing?
Evening dosing aligns with natural overnight GH pulses and is the most common research protocol.
Disclaimer: Information on this page is for research and educational use only. Research compounds sold by AUSPEPS are not approved for human consumption and are intended exclusively for laboratory research.